Investor Presentaiton

Synthesis (CDMO) Division 85 78 148 100 116 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY22 • Revenue from Custom Synthesis division showed a growth of 36% (YoY) Total Number of Active Projects in the CDMO division stood at 49 as on Q2 FY21 Incorporated Wholly Owned Subsidiary to give increased focus and eventually dedicated R&D and Manufacturing Working with Large Global Innovator Pharmaceutical Companies, mid and small Biotech Companies Commercial supplies on-going for 4 products Cr 8 LAURUS Labs Knowledge Innovation. Excelence

View entire presentation